Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06860984 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jun 20, 2026 → Jun 20, 2027
See other at-risk trials from Tanta University

Record History

  1. Primary completion pushed from Jun 20, 2026 to Jun 20, 2027 Completion pushed from Jul 10, 2026 to Jul 10, 2027v5 Show 1 more changeShow less
    • Completion pushed from Jul 10, 2026 to Jul 10, 2027
  2. Primary completion date: Jun 20, 2025 to Jun 20, 2026 Completion date: Jul 10, 2025 to Jul 10, 2026v4 Show 1 more changeShow less
    • Completion date: Jul 10, 2025 to Jul 10, 2026
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruiting Site details revisedv2 Show 1 more changeShow less
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.
Trial Details
NCT Number NCT06860984
Lead Sponsor Tanta University
Conditions Biliary Disease
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov